8-K: TriSalus Life Sciences Reports Strong Q4 and Full Year 2024 Results, Reaffirms Optimistic 2025 Guidance

TriSalus Life Sciences announces a 44% increase in Q4 revenue and a 59% increase in full-year revenue for 2024, alongside reaffirmed guidance for significant growth and profitability in 2025.

Summary

• TriSalus Life Sciences reported its financial results for Q4 and the full year 2024.
• The company achieved $8.3 million in revenue for Q4 and $29.4 million for the full year, representing growth of 44% and 59%, respectively, compared to the prior year periods.
• Gross margin was 85% for Q4 and 86% for the full year.
• TriSalus reaffirmed its 2025 guidance, expecting revenue growth greater than 50%, a reduction in operating expenses greater than 20%, positive EBITDA, and positive cash flow in the second half of 2025.
• The company expanded its product portfolio with the launch of the TriNav LV Infusion System and TriGuide Guiding Catheter.
• The DELIVER clinical program is advancing to demonstrate the impact of PEDD technology.
• Enrollment was completed in the PERIO-03 Phase 1 trial investigating nelitolimod in locally advanced pancreatic cancer, with final data expected mid-2025.
• Positive Phase 1 results from the PERIO-01 trial were presented at SITC in November 2024.
• William Valle and Dr. Gary Gordon joined the Board of Directors, and Sean Murphy rejoined the Board.
• TriSalus secured a $10 million drawdown under its existing credit facility with OrbiMed, ensuring financial flexibility through the end of 2025.
• Operating Cash Flow in the fourth quarter of 2024 was ($5.7) million, reflecting a notable improvement compared to the previous quarter amount of ($10.8) million.
• Cash and Cash Equivalents were $8.5 million as of December 31st, 2024.
• The Company will file a Form 12b-25, Notification of Late Filing, with the SEC related to the Company's Annual Report on Form 10-K for fiscal year 2024 due to errors identified in determining the Company's stock-based compensation and clinical trial related research and development expense timing in 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, high gross margins, and reaffirmed guidance for future profitability. The company is expanding its product portfolio and advancing clinical programs, indicating a promising future. However, the delay in filing the 10-K report and the net losses temper the overall sentiment slightly.

Positives

• Significant revenue growth in 2024, with a 59% increase year-over-year.
• High gross margins of 85% in Q4 and 86% for the full year.
• Reaffirmed guidance for strong revenue growth and profitability in 2025.
• Expansion of the product portfolio with new devices.
• Advancement of clinical programs, including the DELIVER program and trials for nelitolimod.
• Strengthened Board of Directors with the addition of experienced members.
• Secured additional funding to extend the cash runway through 2025.
• Operating Cash Flow improved in the fourth quarter of 2024 compared to the previous quarter.

Negatives

• The company will file a Form 12b-25, Notification of Late Filing, with the SEC related to the Company's Annual Report on Form 10-K for fiscal year 2024 due to errors identified in determining the Company's stock-based compensation and clinical trial related research and development expense timing in 2024.
• The financial information included in the press release is unaudited and subject to change.
• The company reported a net loss available to common stockholders of $(10,108) thousand for the three months ended December 31, 2024 and $(30,045) thousand for the twelve months ended December 31, 2024.

Risks

• The company's future clinical results may not be consistent with patient data generated during the Company's clinical trials.
• The company's ability to remain in compliance with all its obligations under the credit facility to avoid an event of default.
• The company may continue to raise capital through the issuance and sale of its equity securities to fund its operations.
• The company may not be able to achieve the applicable revenue requirements to access additional financing under the credit facility.
• Changes in expected or existing competition or market conditions.
• Unexpected litigation or other disputes.
• Unexpected expensed costs.

Future Outlook

TriSalus anticipates revenue growth greater than 50% in 2025, a reduction in operating expenses greater than 20%, positive EBITDA for the full year, and positive cash flow in the second half of the year.

Management Comments

• We achieved commercial and clinical progress throughout 2024, and positioning TriSalus for greater success in 2025, said Mary Szela, President and Chief Executive Officer of TriSalus Life Sciences.
• We achieved $29.4 million in total revenue, marking 59% growth year-over-year, and continue to expect to deliver greater than 50% revenue growth in 2025.
• Additionally, we anticipate reducing operating expenses by more than 20%, achieving positive EBITDA for the full year, and achieving positive cash flow in the second half of the year.
• We were also pleased to strengthen our Board of Directors with the additions of William Valle and Dr. Gary Gordon.
• Additionally, we want to sincerely thank Sean Murphy for his leadership in guiding the Company through the process of going public, a milestone that would not have been possible without his dedication and expertise.
• We are thrilled to welcome him back to the Board of Directors and look forward to his continued contributions to our success, concluded Ms. Szela.

Industry Context

TriSalus is operating in the oncology-focused medical technology sector, specifically targeting liver and pancreatic tumors. The company's focus on innovative drug delivery technology and immunotherapy aligns with the broader industry trend of developing more targeted and effective cancer treatments. The expansion into the $375 million liver embolization market and the potential $400 million market opportunity in thyroid disease positions TriSalus to compete with established players in these areas.

Comparison to Industry Standards

• Comparing TriSalus's 59% revenue growth in 2024 to other medical technology companies in the oncology space, this growth rate is relatively high, suggesting strong market adoption of their products.
• Companies like Boston Scientific and Medtronic, while much larger, often see more modest growth rates in their medical device segments.
• The gross margins of 85-86% are also strong, indicating efficient cost management and pricing strategies, and are comparable to other high-margin medical device companies.
• The focus on achieving positive EBITDA and cash flow in 2025 is a critical step for TriSalus, as many smaller medical technology companies struggle to achieve profitability in their early stages.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance and future growth prospects.
• Employees: Positive impact due to company growth and stability.
• Customers: Positive impact due to expanded product portfolio and improved treatment options.
• Patients: Positive impact due to advancements in cancer treatment and potential for improved outcomes.
• Creditors: Positive impact due to improved financial stability and cash flow.

Next Steps

• File the Annual Report on Form 10-K with the SEC.
• Continue advancing the DELIVER clinical program.
• Await final data from the PERIO-03 Phase 1 trial in mid-2025 and determine next steps.
• Seek strategic partnerships to advance the immunotherapy program.
• Focus on achieving positive EBITDA and cash flow in 2025.

Key Dates

Keywords

TriSalus Life Sciences, Financial Results, Revenue Growth, EBITDA, Cash Flow, Oncology, Medical Technology, Nelitolimod, PEDD, TriNav, Clinical Trials